BloodCounts! breakthrough in disease detection 1 of 6
Uncovering the regulatory blueprint for early mammalian organ formation 2 of 6
Targeting nearby ‘normal’ cells could improve survival rates 3 of 6
Insight into the development of lymphoma 4 of 6
A BLUEPRINT for blood cells: major epigenetic study 5 of 6
Life-saving discovery and commercial success 6 of 6
The University of Cambridge Department of Haematology is located at the Cambridge Biomedical Campus and the Wellcome Trust Genome Campus. It has laboratories in the Jeffrey Cheah Biomedical Centre, the Cambridge Institute for Medical Research, NHS Blood and Transplant Blood Centre and the Wellcome Sanger Institute. The Head of Department is Professor Brian Huntly.
The department has four main goals:
- To conduct internationally competitive biomedical research.
- To provide education in medical aspects of haematology to undergraduate scientists and medical students.
- To provide postgraduate education, largely through the provision of PhD students.
- To contribute to the clinical activities of the Addenbrooke's Department of Haematology.
Recent publications
Bonfiglio S, Sutton LA, Ljungström V, ... Ghia P. BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023 Jan 25:bloodadvances.2022008821.
Tomás-Daza L, Rovirosa L, López-Martí P, Nieto-Aliseda A, Serra F, Planas-Riverola A, Molina O, McDonald R, Ghevaert C, Cuatrecasas E, Costa D, Camós M, Bueno C, Menéndez P, Valencia A, Javierre BM. Low input capture Hi-C (liCHi-C) identifies promoter-enhancer interactions at high-resolution. Nat Commun. 2023 Jan 17;14(1):268.
Edginton-White B, Maytum A, Kellaway SG, Goode DK, Keane P, Pagnuco I, Assi SA, Ames L, Clarke M, Cockerill PN, Göttgens B, Cazier JB, Bonifer C. A genome-wide relay of signalling-responsive enhancers drives hematopoietic specification. Nat Commun. 2023 Jan 17;14(1):267.
Mitchell CA, Verovskaya EV, Calero-Nieto FJ, Olson OC, Swann JW, Wang X, Hérault A, Dellorusso PV, Zhang SY, Svendsen AF, Pietras EM, Bakker ST, Ho TT, Göttgens B, Passegué E. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat Cell Biol. 2023 Jan;25(1):30-41.
Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, Riviere J, Baille M, Benbarche S, Renou L, Fagnan A, Thirant C, Federici L, Touchard L, Lecluse Y, Jetten A, Geoerger B, Lapillonne H, Solary E, Gaudry M, Meshinchi S, Pflumio F, Auberger P, Lobry C, Petit A, Jacquel A, Mercher T. High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia. Leukemia. 2022 Dec 30.
Agrawal-Singh S, Bagri J, Giotopoulos G, Azazi D, Horton SJ, Lopez CK, Anand S, Bach AS, Stedham F, Antrobus R, Houghton JW, Vassiliou GS, Sasca D, Yun H, Whetton AD, Huntly BJP. HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia. Blood. 2022 Dec 28:blood.2022016528.
Berastegui N, Ainciburu M, Romero JP, et al. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes. Nat Commun. 2022 Dec 9;13(1):7619.
Faille A, Warren AJ. Teaching old drugs new tricks. Elife. 2022 Dec 8;11:e84702.
Braschi B, Bruford EA, Cavanagh AT, Neuman SD, Bashirullah A. The bridge-like lipid transfer protein (BLTP) gene group: introducing new nomenclature based on structural homology indicating shared function. Hum Genomics. 2022 Dec 2;16(1):66.
Cone Sullivan JK, Gleadall N, Lane WJ. Blood Group Genotyping. Clin Lab Med. 2022 Dec;42(4):645-668.
Gassner C, Castilho L, Chen Q, Clausen FB, Denomme GA, Flegel WA, Gleadall N, Hellberg Å, Ji Y, Keller MA, Lane WJ, Ligthart P, Lomas-Francis C, Nogues N, Olsson ML, Peyrard T, Storry JR, Tani Y, Thornton N, van der Schoot E, Veldhuisen B, Wagner F, Weinstock C, Wendel S, Westhoff C, Yahalom V, Hyland CA. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Blood Group Terminology Report of Basel and three virtual business meetings: Update on blood group systems. Vox Sang. 2022 Nov;117(11):1332-1344.
Rayner C, Coleman JRI, Skelton M, Armour C, Bradley J, Buckman JEJ, Davies MR, Hirsch CR, Hotopf M, Hübel C, Jones IR, Kalsi G, Kingston N, Krebs G, Lin Y, Monssen D, McIntosh AM, Mundy JR, Peel AJ, Rimes KA, Rogers HC, Smith DJ, Ter Kuile AR, Thompson KN, Veale D, Wingrove J, Walters JTR, Breen G, Eley TC. Patient characteristics associated with retrospectively self-reported treatment outcomes following psychological therapy for anxiety or depressive disorders - a cohort of GLAD study participants. BMC Psychiatry. 2022 Nov 18;22(1):719.
Meduri E, Breeze C, Marando L, Richardson SE, Huntly BJP. The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome. iScience. 2022 Nov 17;25(12):105622.
Bruford EA, Braschi B, Haim-Vilmovsky L, Jones TEM, Seal RL, Tweedie S. The importance of being the HGNC. Hum Genomics. 2022 Nov 15;16(1):58.
Dornburg A, Mallik R, Wang Z, Bernal MA, Thompson B, Bruford EA, Nebert DW, Vasiliou V, Yohe LR, Yoder JA, Townsend JP. Placing human gene families into their evolutionary context. Hum Genomics. 2022 Nov 11;16(1):56.
Surendran P, Stewart ID, Au Yeung VPW, et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat Med. 2022 Nov 10.
Gordon J, Chapus FL, Viverette EG, Williams JG, Deterding LJ, Krahn JM, Borgnia MJ, Rodriguez J, Warren AJ, Stanley RE. Cryo-EM reveals the architecture of the PELP1-WDR18 molecular scaffold. Nat Commun. 2022 Nov 9;13(1):6783.
Dawson MA, Borthakur G, Huntly B, et al. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clin Cancer Res. 2022 Nov 9:CCR-22-1284.
Lenaerts A, Kucinski I, Deboutte W, Derecka M, Cauchy P, Manke T, Göttgens B, Grosschedl R. EBF1 primes B-lymphoid enhancers and limits the myeloid bias in murine multipotent progenitors. J Exp Med. 2022 Nov 7;219(11):e20212437.
Butler-Laporte G, Povysil G, Kosmicki JA, et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022 Nov 3;18(11):e1010367.
Oeffner RD, Croll TI, Millán C, Poon BK, Schlicksup CJ, Read RJ, Terwilliger TC. Putting AlphaFold models to work with phenix.process_predicted_model and ISOLDE. Acta Crystallogr D Struct Biol. 2022 Nov 1;78(Pt 11):1303-1314.
Terwilliger TC, Poon BK, Afonine PV, Schlicksup CJ, Croll TI, Millán C, Richardson JS, Read RJ, Adams PD. Improved AlphaFold modeling with implicit experimental information. Nat Methods. 2022 Nov;19(11):1376-1382.
Cooper DJ, Lear S, Watson L, et al. A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital. J Infect. 2022 Nov;85(5):557-564.
The NIHR BioResource is a panel of volunteers, with and without health conditions, who will participate in research studies investigating the links between genes, the environment, health and disease enabling scientific discoveries as well as facilitating translational medicine for the benefit of patients.They donate their DNA via a blood or saliva sample which is used together with other information, such as gender, ethnicity, lifestyle and health information to match them to specific research studies. The NIHR Cambridge Centre is one of 13 centres which make up the NIHR BioResource.
Cambridge Blood and Stem Cell BioBank
The Cambridge Blood and Stem Cell Biobank is a tissue bank for samples from patients with haematological malignancies and normal individuals, including cord blood. We are also the repository for the UK Myeloproliferative Disorders (MPD) sample bank, and several clinical trials for this group of disorders. The bank has collected over 15,000 blood and bone marrow-derived samples to date from patients with haematological malignancies and approximately 2600 normal individuals, all curated in a bespoke database designed to facilitate research activities. Existing samples and prospective collections are available to researchers working on ethically approved studies in malignant blood disorders and normal blood development, and 4800 samples have been transferred to researchers both in the UK and internationally.
Haematology at Cambridge